Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reconsidering Medstone STS Lithotripter PMA For Gallstone Treatment

This article was originally published in The Gray Sheet

Executive Summary

Medstone International is developing a protocol for a post-approval clinical study of the firm's STS lithotripter for gallstone treatment as FDA begins to revisit its August 1998 decision to reject the firm's premarket approval application.

You may also be interested in...



Medstone STS Lithotripter Approvable For Gallstone Treatment - FDA Panel

Medstone International should conduct post-approval studies of its STS lithotripter in combination with Novartis' Actigall (ursodiol) anti-gallstone drug to fragment biliary stones, FDA's Gastroenterology and Urology Devices Panel recommended April 30.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.

UsernamePublicRestriction

Register

MT013216

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel